Drug discovery and a new carcinogenic process in the clear cell adenocarcinoma of uterine body

目的：我们已报道mTOR-HIF通路在卵巢透明细胞腺癌(OCCA)中被特异性激活，其激活与卵巢透明细胞腺癌预后不良有关。本研究以预后较差的II型子宫内膜癌为研究对象，研究mTOR-HIF相关因素的动态变化。方法：对27例II型子宫内膜癌组织中mTOR-HIF相关因子进行免疫组织化学染色和临床病理分析。结果：p-mTOR、HIF-1a和HDAC7在所有II型子宫内膜癌中均有不同程度的表达。在透明细胞腺癌中，mTOR-HIF通路的表达水平较高，但差异无统计学意义。

Purpose: We have reported that the mTOR-HIF pathway is specifically activated in ovarian clear cell adenocarcinoma (OCCA), and that its activation is a factor related to a poor prognosis of this cancer. In the present study, we focused on Type II endometrial cancer, which has a poor prognosis compared with Type I cancer, and studied the dynamics of mTOR-HIF-related factors. Methods: We performed immunohistochemical staining and clinicopathologic analysis of mTOR-HIF-related factors in 27 patients (Type II endometrial cancer). Results: Expression of phospho-mTOR (p-mTOR), HIF-1a, and HDAC7 was detected at different levels in all of the Type II endometrial cancers. The level of expression tended to be higher in clear cell adenocarcinoma, but the difference was not significant.Discussion: In the present study, activation of the mTOR-HIF pathway was observed in all patients with Type II endometrial cancer regardless of the histology.